Related references
Note: Only part of the references are listed.Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: a prospective observational study
Ahmad Al Rifai et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2011)
Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio
Sharon J. Gardiner et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2011)
Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease
A. Ansari et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine
Mark E. Gerich et al.
JOURNAL OF CROHNS & COLITIS (2010)
Combination of thiopurines and allopurinol: Adverse events and clinical benefit in IBD
Shail M. Govani et al.
JOURNAL OF CROHNS & COLITIS (2010)
Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis
J. P. Gisbert et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease
Yvette Leung et al.
JOURNAL OF CROHNS & COLITIS (2009)
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
Eliza Prefontaine et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2009)
Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease
A. Ansari et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: A review of four cases and the literature
Todd N. Witte et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY (2008)
Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol
Rupert W. L. Leong et al.
EXPERT OPINION ON DRUG SAFETY (2008)
Initial Clinical Experience with Allopurinol-Thiopurine Combination Therapy in Pediatric Inflammatory Bowel Disease
Riad M. Rahhal et al.
INFLAMMATORY BOWEL DISEASES (2008)
Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine
Miles P. Sparrow et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: A meta-analysis
MT Osterman et al.
GASTROENTEROLOGY (2006)
Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine
MP Sparrow et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Thiopurine S-methyltransferase polymorphisms:: efficient screening method for patients considering taking thiopurine drugs
B Wusk et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis
B Wusk et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2004)
Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease - Implications for therapy
LJJ Derijks et al.
THERAPEUTIC DRUG MONITORING (2004)
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease
MC Dubinsky et al.
GASTROENTEROLOGY (2002)
Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease
C Cuffari et al.
GUT (2001)
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease
MC Dubinsky et al.
GASTROENTEROLOGY (2000)